Literature DB >> 10458485

Infantile pulmonary alveolar proteinosis with interstitial pneumonia: bilateral simultaneous lung lavage utilizing extracorporeal membrane oxygenation and steroid therapy.

T Ito1, M Sato, T Okubo, I Ono, J Akabane.   

Abstract

An infant with refractory pulmonary alveolar proteinosis (PAP) associated with severe interstitial pneumonia is described. Although she was treated by bilateral simultaneous lung lavage utilizing extracorporeal membrane oxygenation and steroid therapy, she died of progressive respiratory failure 28 days after admission. Histologic examination of lung autopsy specimen showed only partial alveolar spaces to be filled with a dense PAS positive granular eosinophilic material and showed severe interstitial pneumonia with marked fibrosis of alveolar walls and interstitium. The lung lavage seemed to be effective for PAP because the effluent fluid sufficiently became clear and the PAS positive material was detected only in partial alveoli. The full venoarterial cardiopulmonary bypass with extracorporeal membrane oxygenation seemed to be very useful to support bilateral lung lavage for small infants. The refractory symptoms and failure of treatment were resulted from the association of severe interstitial pneumonia. In neonates or infants with PAP and severe interstitial pneumonia with poor response for steroid therapy, the lung transplantation should be considered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458485     DOI: 10.1620/tjem.187.279

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  2 in total

1.  Therapeutic lung lavages in children and adults.

Authors:  Christian Paschen; Karl Reiter; Franz Stanzel; Helmut Teschler; Matthias Griese
Journal:  Respir Res       Date:  2005-11-22

2.  Whole lung lavage of nine children with pulmonary alveolar proteinosis: experience in a tertiary lung center.

Authors:  Radpay Badiozaman; Parsa Tahereh; Dabir Shideh; Boloursaz Mohammadreza; Arbab Ahmadreza; Tabatabaei Seyyedahmad
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.